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reactions. This is further supported by
comparable studies in athymic (" nude ")
mice, where admixture with BCG prevented
subcutaneous development of rat tumour cell
inocula.
The implication from these findings is that
localized BCG treatment may still be applic-
able clinically, even when immunosuppression
has resulted from chemotherapy or radio-
therapy.
TUMOUR ANTIGEN IN HUMAN CAN-
CER PATIENTS' SERA. J. G. BOWEN,
Cancer Research Campaign Laboratories,
University of Nottingham.
Previous studies (Baldwin, Bowen and
Price, Br. J. Cancer, 1973, 28, 16) have
shown that tumour specific antigen can be
isolated from the serum of rats bearing a
transplanted aminoazo dye-induced hepa-
toma. The present study was undertaken to
determine if the sera of human bladder
cancer patients contained a tumour specific
antigen. Sera were fractionated by Sepha-
dex G-150 gel chromatography and material
with a molecular weight less than 150,000
Daltons examined for the presence of tumour
specific antigen by the leucocyte migration
inhibition test using leucocytes from bladder
cancer patients, other cancer patients and
non-cancer hospital patients. Antigen could
be detected in the sera of patients bearing
turnour in situ and those within one month of
tumour elimination. Patients tumour free
for longer than 3-4 years lacked reactivity
against the tumour bearer serum fraction.
CELL MEDIATED CYTOTOXICITY
(CMC) IN PATIENTS WITH ACUTE
MYELOBLASTIC LEUKAEMIA RE-
CEIVING IMMUNOTHERAPY. G. M.
TAYLOR, R. HARRIS and C. B. FREEMAN,
Department of Medical Genetics, St Mary's
Hospital, Manchester.
The effect of immunotherapy with allo-
geneic leukaemic blasts in patients with
acute myeloid leukaemia (AML) was assessed
by stimulating lymphocytes from these
patients when in remission and also lympho-
cytes from normal donors with immuno-
therapy blasts (I blasts), Burkitt's lymphoma
(RAJI) cells and normal lymphoblastoid
cells (LCL). After 6 days in culture,
stimulated lymphocytes were cross-tested for
cell mediated cytoxicity (CMC) against 51Cr
-labelled target cells of the same origin as
those used to stimulate the lymphocytes.
Patients on immunotherapy, and stimulated
invitrowithIblasts invariably showed ahigher
level of line directed CMC compared with
normals whereas cross tests of the same
lymphocytes against RAJI and LCL cells
revealed lower, though reproducible, cytoto-
xicity. RAJI generally failed to produce
cytotoxicity either in patients or normals,
whilst LCL induced cytotoxicity in both
sources oflymphocytes, withsome evidence of
cross-reactivity. Immunotherapy patients
seem topossessa pool oflymphocytes capable
of restimulation in vitro to give high levelsof
CMC,apropertywhichcouldbeusefulforevalu-
ating the response to immunotherapy ofAML
patients and which could aid the search for
tumour associated antigens on autochthonous
blasts. Moreover, CMC response is direct
evidence that the measures being used at
present to induce cell mediated immunity
in these patients do in fact work and may
be of value in selecting cells for use in
immunotherapy.
ACTIVE IMMUNOTHERAPY IN
ACUTE MYELOID LEUKAEMIA. C. B
FREEMAN, G. M. TAYLOR and R. HARRIS,
St Mary's Hospital, Manchester, and C. G.
GEARY, J. E. MACIVER and I. W. DELAMORE,
Manchester Royal Infirmary.
The duration of first remission in a small
group (7) of acute myeloid leukaemia (AML)
patients maintained with irradiated allo-
geneic leukaemia cells and BCG, after initial
consolidation chemotherapy, was similar to
that achieved in comparable trials using
conventional chemotherapy (Freeman et al.,
Br. med. J., 1973, iv, 571). In a second series
of 20 patients in the MRC 6th AML Trial, to
whom the same immunotherapy was given
but without prior consolidation chemo-
therapy, the median duration of first re-
mission was considerably shorter.
Compared with patients receiving other
therapeutic protocols, there was a remarkably
high reinduction rate following relapse in
both series of patients maintained with
immunotherapy alone (second remissions in
group 1: 5/6, group 2: 12/18 with four third
remissions) and the overall survival figures
are very encouraging (group 1: 4/7 alive,
current mean survival 115 weeks, group 2:
13/20, current mean survival 50 weeks).